Abera Bioscience AB is a Swedish biotech company headquartered in Stockholm. We are dedicated to develop novel vaccines and vaccine development technologies to improve health worldwide. The Company's unique expertise in Biochemistry and Molecular Microbiology is based on many years of research and has generated a patented platform technology for the development of novel vaccines. Abera brings Outer Membrane Vesicle (OMV) technology to the next level by decorating their surface with a palette of antigens at a high density. To this end, Abera has adapted a natural system for bacterial protein secretion into the most efficient and versatile system for surface display of antigens known today. Abera's platforms allows the development of efficient multivalent, multi-stage vaccines for oral and nasal administration. It also enables faster and more cost-effective production. Abera's OMV-based vaccines can be manufactured within 14-30 days.
Location: Sweden, Stockholm
Employees: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Beijer Ven... | beijervent... |
Mentions in press and media 1
| Date | Title | Description |
| 10.04.2025 | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology Thu, Apr 10, 2025 08:00 CET Report this content The study was conducted in partnership with Abera Bioscience, a platform and vaccine d... |